https://www.selleckchem.com/pr....oducts/Imatinib-Mesy
05), younger age (odds ratio 2.59, 95% CI 2.18-3.07, p less then 0.05), anxiety (odds ratio 2.57, 95% CI 1.94-3.40, p less then 0.05), history of morning sickness (odds ratio 1.97, 95% CI 1.46-2.65, p less then 0.05), and low alcohol intake (odds ratio 1.94, 95% CI 1.68-2.24, p less then 0.05). Conclusions Oncologists can use these factors prior to the initiation of a chemotherapy regimen to identify patients at risk for CINV, in order to focus on more comprehensive antiemetic treatment options for those high-risk patients. Th
Like
Comment
Share
